Drugs in R & D

, Volume 1, Issue 4, pp 317–318 | Cite as

Landiolol

ONO 1011
Section 1: Antiarrhythmic Agent Adis R&D Profile
  • 4 Downloads

Keywords

Atrial Fibrillation Adis International Limited Atrial Flutter Esmolol Landiolol 

References

  1. 1.
    Atarashi H, Kuruma A, Ino T, et al. ONO-1101: a new ultrashort acting beta-adrenergic blocker: initial study of efficacy, safety and pharmacokinetics. Cardiovasc Drugs Ther 1993; 7 Suppl. 2: 444Google Scholar
  2. 2.
    Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull 1992; 40: 1462–9PubMedCrossRefGoogle Scholar
  3. 3.
    Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4949–78Google Scholar
  4. 4.
    Kato K, Iinuma H, Hayakawa H, et al. Clinical effect of intravenous infusion of landiolol hydrochloride (ONO-1101) on paroxysmal atrial fibrillation and atrial flutter: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4903–24Google Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations